Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dell Technologies Inc (DELL) vs Summit Therapeutics Inc (SMMT) Price & Performance

Dell Technologies IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Dell Technologies Inc vs Summit Therapeutics Inc — how do they compare? Dell Technologies Inc trades at $481.84 (market cap $284.93B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Dell Technologies Inc is far larger — about 23.6× Summit Therapeutics Inc's market cap, and Dell Technologies Inc pays a 0.57% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

DELLSMMT
Market Cap
$284.93B$12.06B
Sector
TechnologyHealth
52-Week High
$467.27$26.98
52-Week Low
$111.10$12.55
Enterprise Value
$304.51B$11.39B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dell Technologies Inc

Dell Technologies stock trades at $478.30, up 4.45% in the last session, reflecting strong momentum amid AI-driven server demand. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $4.86 surpassing the $2.96 forecast. The technical outlook is bullish, with the price above key moving averages, while fundamentals show revenue growth to $95.57 billion in 2025 and a net income margin of 6.28%.

The outlook remains positive given robust analyst sentiment, with a consensus price target of $503.76 implying upside. Key risks include valuation concerns at a P/E of 35.14 and potential margin pressure from memory shortages. Continued execution on AI server backlog and commercial PC refresh cycles are critical for sustained growth.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT